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Abstract Abnormal retention of vF508 CFTR (cystic ¢brosis
transmembrane conductance regulator) in the endoplasmic retic-
ulum is a major cause of cystic ¢brosis (CF). We show that
calnexin v185^520 but not calnexin can partially reverse the
mislocalization of vF508 CFTR. This 256-amino acid protein
has neither the transmembrane domain nor the P domain of
calnexin. Calnexin v185^520 interacted with CFTR directly,
and was secreted into the extracellular compartment over
time. Forty-eight hours after transfection into CHO cells, cal-
nexin v185^520 increased the conversion of immature vF508
CFTR into mature vF508 CFTR. In immortalized human CF
cell lines expressing vF508 CFTR, a halide e¥ux assay showed
that calnexin v185^520 partially restored CFTR function.
These data indicate that calnexin v185^520 may give a clue
to develop the therapeutic way of cystic ¢brosis with vF508
CFTR. 1 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cystic ¢brosis transmembrane conductance regulator
(CFTR) is a plasma membrane Cl3 channel regulated by
cAMP-dependent phosphorylation and by intracellular ATP
[1^4]. Mutations in the CFTR gene lead to the absence or
malfunction of a regulated Cl3 channel in the apical mem-
brane of secretory epithelia resulting in the clinical symptoms
of cystic ¢brosis (CF) [5^7]. Therefore, potential CF therapies
are aimed at overcoming the functional impairment of various
mutant CFTRs, particularly vF508 CFTR, in which a phenyl-
alanine at position 508 is deleted from the ¢rst nucleotide-
binding fold. This mutation is found in approximately 70%
of CF chromosomes and results in a severe form of the dis-
ease; more than 90% of CF patients have at least one vF508
allele [8,9].
Clues as to how this mutation compromises CFTR function
were ¢rst provided by Cheng et al. following studies of vF508
CFTR biosynthesis in transfected COS cells [10]. The failure
of N-linked oligosaccharides processing beyond the immature
high-mannose form suggested that this mutant was trapped
within the endoplasmic reticulum (ER). Understanding the
basis of this intracellular retention would be of great value,
since vF508 CFTR is functionally competent in model situa-
tions where it is able to reach the plasma membrane. Func-
tional Cl3 channel activity is found in the plasma membrane
when mammalian cells expressing vF508 CFTR are grown at
reduced temperatures [11] or when this mutant is expressed in
amphibian and insect cells [2] or is puri¢ed and reconstituted
in planar lipid bilayers [12]. Although some di¡erences remain
in the channel characteristics reported among the various
groups, the primary e¡ect of the vF508 mutation in mamma-
lian cells is not functional impairment, but rather mislocaliza-
tion of the protein product.
Overcoming the biosynthetic arrest of vF508 CFTR and
promoting the tra⁄cking of this mutant to the plasma mem-
brane require knowledge of the retention mechanism. The ER
quality control machinery participates in the ER localization
of vF508 CFTR [13^16]. This machinery involves a variety of
mechanisms to ensure that only correctly folded and as-
sembled proteins are transported to the late secretory path-
way, while non-native proteins are retained in the ER and
eventually targeted for degradation [17,18].
Intracellular retention of mutant proteins has often been
linked to prolonged interactions with molecular chaperones
in the ER [17]. Chaperones associate transiently with many
nascent proteins and are thought to promote productive fold-
ing by preventing the aggregation of folding intermediates.
However, proteins that are unable to fold correctly or assem-
ble into complete oligomeric complexes often exhibit pro-
longed association with chaperones, a property that may con-
tribute to their retention in the ER. Calnexin (CNX), a lectin-
like transmembrane protein located in the ER, has been
shown to associate transiently with a large number of newly
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synthesized proteins, including both transmembrane and se-
cretory proteins [18,19]. In addition, calnexin displays a pro-
longed binding to certain misfolded proteins and to incom-
pletely assembled forms of oligomeric proteins [18,19]. It was
reported that calnexin associates speci¢cally with newly syn-
thesized CFTR and vF508 CFTR and that vF508 CFTR
retains the association with calnexin throughout its life,
whereas wild-type CFTR escapes the association and exits
the ER [14]. The binding of calnexin to nascent proteins in
vivo generally requires the formation of monoglucose oligo-
saccharides [19]. However, non-sugar-mediated interactions
such as polypeptide-based interactions have also been re-
ported [20,21]. Here we show that calnexin v185^520, which
lacks calnexin’s transmembrane domain and P domain, par-
tially restores the function of vF508 CFTR. calnexin v185^
520 interacted with CFTR directly, and was secreted into the
extracellular compartment over time. Forty-eight hours after
transfection into CHO cells, calnexin v185^520 increased the
conversion of immature vF508 CFTR into mature vF508
CFTR. In immortalized human CF cell lines expressing
vF508 CFTR, a halide e¥ux assay showed that calnexin
v185^520 partially restored CFTR function.
2. Materials and methods
2.1. cDNA cloning
Total RNA from hamster trachea was isolated with Isogen (Nippon
Gene) according to the manufacturer’s protocol. Total RNA was
reverse transcribed (RT) to cDNA at 42‡C for 30 min. The cDNA
was denatured for 3 min at 95‡C, followed by 40 cycles of ampli¢ca-
tion by polymerase chain reaction (PCR). Each cycle consisted of
denaturation at 95‡C for 30 s, annealing at 62‡C for 30 s, and a
primer extension at 72‡C for 1.5 min. The RT-PCR product was
denatured for 8 min at 95‡C followed by 40 cycles of ampli¢cation
by nested PCR. Each cycle consisted of denaturation at 95‡C for
1 min, annealing at 62‡C for 1 min, and primer extension at 72‡C
for 2 min. The RT-PCR and nested PCR primer sequences used were
as follows: RT primer and hamster calnexin forward primer: 5P-
GGTCCTCTCCTAGGACCACTCTTGC-3P ; hamster calnexin re-
verse primer: 5P-GTCCCCGGGCAGGCTAGAGATCATGGA-3P ;
nested forward primer: 5P-CTCTCTTCGTGGCTTTCTGTT-3P ;
nested reverse primer: 5P-ATGGAAGGGAAGTGGTTGCTGTGT-
ATG-3P. The nested PCR product was cloned into a TA cloning
vector and the clones were sequenced.
2.2. Cell culture
16HBE14o3 and CFBE41o3 cells were grown in Eagle’s minimum
essential medium (MEM) with 10% fetal bovine serum and antibiot-
ics. The cells were grown on 35-mm culture dishes coated with human
¢bronectin. CFTR-CHO cells, vF508-CHO cells, and BHK cells sta-
bly expressing a CFTR-green £uorescent protein (GFP) fusion have
been described previously [22]. All cells were incubated at 37‡C in an
atmosphere of 5% CO2^95% air.
2.3. Anti-calnexin v185^520 antibody production
Female BALB/c mice were immunized with the peptide
QFHDKTPQPDVKEE. After the ¢nal immunization, the spleen
was removed and fused with P3U1 myeloma cells. Antibody-positive
hybridomas were subcloned using limiting dilution. The antibody was
puri¢ed from the ascites of pristane-treated BALB/c mice.
2.4. Preparation of recombinant adenoviruses
Calnexin v185^520 and calnexin adenoviruses (both based on ad-
enovirus 5) were produced by homologous recombination in 293 cells
using a TaKaRa Adenovirus Expression Vector Kit (TaKaRa).
2.5. GFP fusion proteins
To construct GFP-CNX, GFP-calnexin v185^520, and GFP-cal-
nexin v185^520 vS (a deletion mutant of the N-terminal 20 amino
acid residues), cDNA (human calnexin, calnexin v185^520, and cal-
nexin v185^520 vS cDNA in the TA cloning vector) was ampli¢ed by
PCR. Each cDNA was denatured for 3 min at 95‡C, followed by
40 cycles of ampli¢cation. Each cycle consisted of denaturation at
94‡C for 1 min, annealing at 64‡C for 1 min, and primer extension
at 72‡C for 1.5 min. PCR products were digested with EcoRI and
BamHI and ligated into the pEGFP vector (Clontech). The PCR
primer sequences used were as follows: pEGFP-CNX and pEGFP-
calnexin v185^520 forward primer: 5P-CAGAATTCGGCTTATGG-
AAGGGAAGTGGTTGC-3P ; pEGFP-calnexin v185^520 vS forward
primer: 5P-CAAATGGGCGGTAGGCGTGTACGG-3P ; pEGFP-
CNX, pEGFP-calnexin v185^520 and pEGFP-calnexin v185^520
vS reverse primer: 5P-CGGGATCCCACTCTCTTCGTGGCTTT-
CTGT-3P. Transfectam (Promega) was used to transfect 2.5 Wg of
pEGFP, pEGFP-CNX, pEGFP-calnexin v185^520, or pEGFP-cal-
nexin v185^520 vS into vF508-CHO cells. Transfected cells were
then incubated for 48 h in growth medium. Images were collected
and analyzed by a Fluoview FV300 confocal laser scanning micro-
scope (Olympus).
2.6. Immuno£uorescence assay
Cells were grown on glass-bottomed culture dishes, ¢xed in 3.7%
paraformaldehyde for 20 min at room temperature, and permeabilized
with 0.5% Triton X for 20 min at room temperature. Fixed cells were
subsequently blocked for 30 min at room temperature with phos-
phate-bu¡ered saline (PBS) containing 1.5% bovine serum albumin
and incubated with anti-calnexin, anti-calreticulin (stressgen), and
anti-calnexin v185^520 antibodies (1:100 dilution) for 1 h at room
temperature. Cells were washed three times with PBS and then stained
with £uorescein isothiocyanate (FITC)-conjugated secondary antibod-
ies (1:100 dilution, Jackson ImmunoResearch Laboratories) for
45 min at room temperature. Cells were washed three times with
PBS and mounted with Vectashield0 mounted medium (Vector Lab-
oratories). Cells were observed and analyzed with a Fluoview FV300
confocal laser scanning microscope (Olympus).
2.7. Immunoprecipitation and Western blotting
CFTR-CHO cells and vF508-CHO cells were infected with calnexin
v185^520, calnexin, or LacZ expression adenovirus (multiplicity of
infection (MOI): 50). Forty-eight hours after infection, all cells were
solubilized with RIPA bu¡er (50 mM Tris^HCl, 150 mM NaCl, 1 mg/
ml sodium deoxycholate and 1% NP-40) containing 1 mM phenyl-
methylsulfonyl £uoride (PMSF). An anti-CFTR (clone: 24-1; Gen-
zyme/Techne) antibody was immobilized on protein G Sepharose
beads (Pharmacia Biotech) and incubated with vF508-CHO cell ly-
sates for 4 h at 4‡C. Immune complexes were washed four times with
RIPA bu¡er and eluted with 2Uconcentrated sodium dodecyl sulfate
(SDS) loading bu¡er. Immunoprecipitated proteins were analyzed by
SDS^polyacrylamide gel electrophoresis (SDS^PAGE) and trans-
ferred to polyvinylidene di£uoride (PVDF) membrane (Millipore),
and probed with the antibodies speci¢ed in the ¢gure legends before
chemiluminescent detection (ECL Western Blotting Detection Re-
agents, Amersham Pharmacia Biotech).
2.8. Metabolic labeling with [35S]methionine
Pulse-chase analysis and immunoprecipitation were carried out as
described previously [23]. CFTR-CHO and vF508-CHO cells were
seeded on 60-mm dishes and grown to 70% con£uence before being
infected. Forty-eight hours after infection, cells were pre-incubated for
30 min in methionine- and cysteine-free KMEM and then labeled for
20 min with 100 WCi/ml of [35S]methionine and [35S]cysteine (s 1000
Ci/mmol, Amersham). For chasing, cells were washed three times with
KMEM and incubated with complete KMEM supplemented with 7%
serum and 0.75 mM methionine for the time periods. The cells were
washed with ice-cold PBS and lysed overnight at 4‡C in 800 Wl RIPA
bu¡er containing 1 mM PMSF. Samples were centrifuged at
15 000Ug for 10 min at 4‡C, and the supernatant was incubated for
4 h at 4‡C with anti-CFTR antibody. Immunoprecipitated proteins
were analyzed by 6% SDS^PAGE, and visualized by autoradiography
(BAS-1800II, Fuji¢lm). The radioactivity associated with CFTR was
quanti¢ed by Image Gauge Ver. 3,4 software (Fuji¢lm).
2.9. 125I e¥ux experiments
125I e¥ux experiments were performed on cells grown on ¢bronec-
tin-coated six-well plates. Con£uent cells were rinsed four times with
1 ml of e¥ux bu¡er (140 mM NaCl, 3.3 mM KH2PO4, 0.83 mM
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Fig. 1. Characterization of calnexin v185^520. A: Expression of calnexin v185^520 and calnexin after transfection of the calnexin v185^520
cDNA using an adenovirus vector. B: Forty-eight hours after infection, all cells were solubilized with RIPA bu¡er. Whole cell lysates (10 Wg)
were subjected to SDS^PAGE on a 7.5% polyacrylamide gel, transferred to PVDF membrane, and blotted with anti-calnexin v185^520 (left) or
anti-calnexin (right) antibody. The expression of calnexin v185^520 by adenovirus was MOI-dependent. Calnexin v185^520 was speci¢cally de-
tected by an anti-calnexin v185^520 antibody. An anti-calnexin antibody also detected calnexin v185^520. The calnexin v185^520 size is ap-
proximately 38 kDa. C: ER localization of transfected calnexin v185^520, endogenous calnexin, and endogenous calreticulin (CRT). All panels
are £uorescence micrographs of vF508-CHO cells ¢xed in 4% paraformaldehyde and permeabilized with 0.5% Triton X. Cells were labeled
with anti-calnexin, anti-calreticulin, or anti-calnexin v185^520 antibodies, and visualized with a FITC-labeled secondary antibody. D: Expres-
sion of GFP-fused proteins. vF508-CHO cells were transfected with 2.5 Wg of pEGFP, pEGFP-CNX, pEGFP-calnexin v185^520, and pEGFP-
calnexin v185^520 vS. Transfected cells were then incubated for 48 h in growth medium. E: Kinetics of newly synthesized calnexin v185^520.
Pulse-chase experiments with [35S]methionine were performed, and calnexin v185^520 was immunoprecipitated after transfection of calnexin
v185^520 adenovirus vector into CFTR-CHO (WT, wild-type) and vF508-CHO cells (vF508). We determined the content of labeled calnexin
v185^520 in the cells and in the culture medium. Quanti¢cation data (right) are shown as percent of total calnexin v185^520. The newly syn-
thesized calnexin v185^520 in the cells at 0 h was regarded as the total calnexin v185^520 content (100%).
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K2HPO4, 1 mM CaSO4, 1 mM MgSO4, 10 mM HEPES, 10 mM
glucose, pH 7.4). After washing, 1 ml e¥ux bu¡er with 20 WCi/ml
of 125I (Amersham) was added to each well and incubated for 1 h at
37‡C. After 1 h, cells were rinsed three times with 1 ml of e¥ux bu¡er,
and 1 ml of e¥ux bu¡er was again added into each well. Samples
were removed at 1.5-min intervals and replaced with fresh bu¡er. This
process was repeated 15^26 times with cAMP treatment cocktail (500
WM CPT-cAMP, 1 mM isobutylmethylxanthine, 10 WM forskolin),
beginning after the fourth e¥ux period. After the last e¥ux interval,
cells were lysed with 0.1 M HNO3 (1 ml) for 2 h at room temperature.
All samples were counted with an autowell gamma counter (ARC-
1000M, Aloka). Total counts equaled the sum of counts from lysed
cells and from all e¥ux samples. E¥ux is shown as the percent of the
total count remaining at the end of each e¥ux period. The percentage
e¥ux was calculated as follows: % e¥ux= (count secreted)/(total
count remaining in the cells each minute)U100.
3. Results
3.1. Characterization of calnexin v185^520
First of all, bands of several sizes were detected on Western
blots using an anti-calnexin antibody against hamster tissues
(data not shown). Since this suggested that some isoforms of
calnexin may exist, we performed a RT-PCR using hamster
trachea mRNA. We cloned the cDNA of a truncated calnexin
isoform (calnexin v185^520, GenBank accession number
AF380341). Calnexin v185^520 was 100% homologous to
the N- and C-termini of hamster calnexin (GenBank accession
number AB071869) (Fig. 1A), and was 99% homologous to
the the N- and C-termini of human calnexin. We found that
the molecular weight of calnexin v185^520 expressed by re-
combinant adenovirus was approximately 38 kDa (Fig. 1A).
Since the C-terminus of calnexin v185^520 has an acidic do-
main with a highly negative charge (like calnexin), the appar-
ent molecular weight on SDS^PAGE is di¡erent from the
calculated molecular weight (28.7 kDa). An immunocyto-
chemical study indicated that the transfected calnexin v185^
520 was localized in the ER, since calnexin v185^520 was
colocalized with ER chaperones such as calnexin and calreti-
culin (Fig. 1B). Calnexin v185^520 includes the N-terminal
ER localization signal sequence of calnexin (residues 1^20)
[24]. Since calnexin v185^520 without the ER localization
signal sequence was localized in the cytosol (Fig. 1C), the
ER localization of calnexin v185^520 was due to the N-ter-
minal ER-localizing signal sequence. The C-terminal ER re-
tention signal (RKPRRE) of calnexin v185^520 might not be
functional in the ER, since the ER retention signal of calnexin
functions in the cytosol. Therefore, we speculated that some
calnexin v185^520 may be secreted into the culture medium.
To examine this possibility, pulse-chase experiments were per-
formed in vF508-CHO and CFTR-CHO cells (Fig. 1D). In
both cells, calnexin v185^520 progressively increased in the
medium as it decreased in the cells, suggesting that calnexin
v185^520 was secreted into the medium. The secreted calnexin
v185^520 produced a doublet that was slightly larger than the
cellular form. The identity and site of the modi¢cation were
unclear.
3.2. Calnexin v185^520 can interact with CFTR
We determined whether calnexin v185^520, which lacks the
P domain, could interact with CFTR. As shown in Fig. 2A,
calnexin v185^520 expressed by a recombinant adenovirus
vector was coprecipitated with vF508 CFTR in vF508-CHO
cells. This interaction seemed to be speci¢c since calnexin
v185^520 was not coprecipitated by protein G Sepharose
beads (data not shown). Although the e⁄ciency of the inter-
action of calnexin v185^520 with vF508 CFTR seems to be
stronger than that of calnexin (lanes 2 and 6 in Fig. 2B), it is
di⁄cult to conclude whether the binding is actually stronger
because the nature of the association remains unclear.
3.3. E¡ect of calnexin v185^520 on the maturation of
vF508 CFTR
To examine whether calnexin v185^520 a¡ects the matura-
tion of vF508 CFTR, we transfected calnexin v185^520
cDNA into vF508-CHO and CFTR-CHO cells with an ad-
enovirus vector, and performed pulse-chase experiments (Fig.
3A). Newly synthesized CFTR has two oligosaccharide chains
and migrates on SDS^polyacrylamide gels as a series of bands
between 130 and 150 kDa in size (immature CFTR). It is
converted to a mature form larger than 175 kDa in the Golgi
apparatus [10]. In CFTR-CHO cells, mature CFTR was ex-
pressed at 3 h. In contrast, vF508 CFTR did not mature, and
may have been mostly degraded by the ubiquitin^proteasome
pathway [25,26]. However, in vF508-CHO cells transfected
with calnexin v185^520, a 175-kDa band that seemed to be
the mature form of vF508 CFTR appeared at a detectable
level after a 3-h chase. Thus, overexpression of calnexin v185^
520 might stimulate the maturation of vF508 CFTR, while
maturation of wild-type CFTR was not inhibited by over-
expression of calnexin v185^520 (Fig. 3A). To determine
whether the mature form of vF508 CFTR induced by calnex-
in v185^520 was localized at the cell surface, the localization
of vF508 CFTR tagged with GFP was examined. As shown in
Fig. 3B, calnexin v185^520 partially alleviated the ER reten-
tion (perinuclear £uorescence) of GFP-fused vF508 CFTR, as
Fig. 2. The interaction of calnexin v185^520 with CFTR. vF508-
CHO cells were infected with or without (control; lanes 1, 5) cal-
nexin v185^520 (lanes 2, 6), calnexin (lanes 3, 7), or LacZ (lanes 4,
8) expression adenovirus (MOI: 50). Forty-eight hours after infec-
tion, all cells were solubilized with RIPA bu¡er. Anti-CFTR (C-ter-
minus) antibody was immobilized on protein G Sepharose beads
and mixed with vF508-CHO cell lysates. Bound proteins were re-
covered by brief centrifugation, resolved on SDS^PAGE, transferred
to PVDF membranes. and blotted with anti-calnexin v185^520 (A)
or anti-calnexin antibodies (B).
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indicated by surface £uorescence (detectable as increased in-
tensity at the perimeter, and a lighter tent-like veil over the
entire surface). However, the surface £uorescence was slightly
less intense than that of cells expressing the GFP-fused wild-
type CFTR. The overexpression of calnexin v185^520 did not
a¡ect the localization of wild-type CFTR (Fig. 3B). Calnexin
v185^520 also did not a¡ect the localization of other ER
membrane proteins such as the IP3 receptor (data not shown).
3.4. Calnexin v185^520 partially restores the function of
vF508 CFTR in human CF cells
Finally, we measured cAMP-activated halide e¥ux as a
functional marker of CFTR using an immortalized human
CF airway epithelial cell line (CFBE41o3) with the vF508
mutation [27]. As illustrated in Fig. 3C, stimulation of normal
human airway epithelial cells (16HBE14o3 [28]) with a cAMP
cocktail (10 WM forskolin, 1 mM isobutylmethylxanthine,
500 WM CPT-cAMP) resulted in a signi¢cant increase in e¥ux
over the baseline. In contrast, cAMP stimulation did not in-
crease the halide e¥ux in CFBE41o3 cells. As expected, trans-
fection of calnexin v185^520 signi¢cantly increased the
cAMP-dependent halide e¥ux in CFBE41o3 cells. Previous
studies reported that lowering the growth temperature to 26‡C
[11], treatment with 1 mM sodium 4-phenylbutyrate (4-PBA)
[29], and treatment with 0.5 M glycerol [30,31] all improved
the processing of vF508 CFTR. In our study, the e¡ect of
calnexin v185^520 was comparable to these positive controls
(Fig. 3C). Its e¡ectiveness was found to be similar in vF508-
Fig. 3. The in£uence of calnexin v185^520 on the maturation of vF508 CFTR. A: CFTR-CHO and vF508-CHO cells were infected with or
without adenovirus expressing calnexin v185^520 (MOI: 50). Cells were pre-incubated in methionine-free medium for 30 min, pulse-labeled
with [35S]methionine (100 WCi/ml) for 20 min, and then chased with methionine-containing medium for the indicated times. Cells were then
solubilized with RIPA bu¡er and immunoprecipitated with an antibody against the CFTR C-terminus. Immunoprecipitates were analyzed by
6% SDS^PAGE and autoradiography. B: Cell surface and intracellular localization of wild-type and vF508 CFTR fused to GFP at the C-ter-
mini in BHK cells. A FITC ¢lter was employed for £uorescence microscopy. GFP fused to wild-type CFTR (WT) is observed over the entire
cell surface and also in a perinuclear distribution (seen as increased intensity below the uniform surface veil). vF508 CFTR fused to GFP
(vF508) forms only perinuclear images. After calnexin v185^520 transfection, vF508 CFTR fused to GFP is observed over the cell surface.
C: Calnexin v185^520 in£uences on halide e¥ux in human CF cells. 125I e¥ux experiments were performed on 16HBE14o3 and CFBE41o3
cells infected with calnexin v185^520 expression adenovirus (MOI: 50). Con£uent cells were loaded with 125I (20 WCi/ml) for 1 h at 37‡C. Sam-
ples were removed at 1.5-min intervals and their radioactivity was counted. The percentage e¥ux was calculated as follows: % e¥ux= (count
secreted)/(total count remaining in the cells each minute)U100. D: E¡ects on halide e¥ux in human CF cells. 125I e¥ux experiments were per-
formed on CFBE41o3 cells infected with calnexin v185^520 expression adenovirus (MOI: 50), or incubated at 26‡C for 72 h, or treated with
1 mM 4-PBA or 0.5 M glycerol for 48 h. The ratio was calculated as follows: ratio (Emax/Epre) = (max % release after cAMP stimulation)/(%
release at time 0) or (max % release after time 0)/(% release at time 0). Data are expressed as mean valuesW S.E.M. Statistical di¡erences are
shown as *P6 0.05, **P6 0.01, ***P6 0.001 against control.
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CHO cells (data not shown). Therefore, calnexin v185^520
can partially restore the function of vF508 CFTR in human
CF cells.
4. Discussion
Our results indicate that calnexin v185^520 partially re-
verses the mislocalization and restores the function of
vF508 CFTR. Based on the present and other ¢ndings, we
have speculated on the mechanism of action of calnexin v185^
520. The recent three-dimensional structural analysis reveals
two unique domain structures of calnexin, a globular domain
(lectin domain) and a long extended arm (P domain), support-
ing a dual role in protein folding [32]. Calnexin v185^520
seems not to possess the complete lectin domain and P do-
main, suggesting that calnexin v185^520 may not a¡ect the
folding of the normal protein through the ER machinery.
Supporting this, overexpression of calnexin v185^520 did
not a¡ect the maturation of wild-type CFTR or the localiza-
tion of the IP3 receptor (data not shown). However, calnexin
v185^520 directly interacted with vF508 CFTR without af-
fecting the interaction between vF508 CFTR and calnexin
(lanes 5 and 6 in Fig. 2B). Although it is conceivable that
the observed coprecipitation of calnexin v185^520 with
vF508 CFTR is responsible for the e¡ects, the exact mecha-
nisms remain unclear. After calnexin v185^520 binds to an
unstable folding intermediate of vF508 CFTR, both might
then be transported together to the late secretory pathway.
We will need to perform further experiments to determine
whether this actually happens.
It remains unclear whether calnexin v185^520 is a unique
gene or a splicing variant of calnexin. Recently, the human
calnexin gene sequence has become available (NCBI accession
number NT_006932), indicating that the amino acid residues
of calnexin at 185 and 520 resided in the middle of exon 7 and
exon 13, respectively. Namely, we could not ¢nd the splicing
sites that can produce calnexin v185^520 in human calnexin
gene. However, we cannot exclude the possibility that calnexin
v185^520 is produced by an unknown splicing mechanism.
In conclusion, calnexin v185^520 partially restored the mat-
uration and function of vF508 CFTR, although not to wild-
type levels. This provides a basis for speci¢c rational ap-
proaches to develop a therapy based on the calnexin v185^
520 sequence. Because the size of calnexin v185^520 cDNA
(771 bp) is easier to handle than that of CFTR cDNA (6.5
kb), calnexin v185^520 may give us a clue for a good gene
therapy candidate not only for CF (vF508 mutation), but also
for other genetic diseases with protein tra⁄cking defects in the
ER, such as familial hypercholesterolemia (class 2 mutations)
[33], emphysema with the Z mutation of the K1-antitrypsin
gene [34], Tay^Sachs disease (one rare mutation) [35], and
congenital sucrase-isomaltase de¢ciency (some mutations)
[36].
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